Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?

Gilead Sciences has outperformed broader equities this year, climbing nearly 30%, driven by strong financial results and regulatory progress. The company's Q2 revenue reached $7.8 billion (up 10% YoY), with HIV products generating $5.7 billion. Recent FDA approvals include Bixlenvo for HIV and Hepcludex for hepatitis delta, while Trodelvy received a label expansion for first-line metastatic triple-negative breast cancer treatment. With a solid dividend yield of 2.2% and flagship products like Biktarvy, Gilead appears attractive for long-term investors despite the stock's recent gains.